These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1752115)

  • 1. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.
    Halstenson CE; Macres M; Katz SA; Schnieders JR; Watanabe M; Sobota JT; Abraham PA
    Clin Pharmacol Ther; 1991 Dec; 50(6):702-12. PubMed ID: 1752115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers.
    Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
    Arzneimittelforschung; 2008; 58(5):220-4. PubMed ID: 18589556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
    Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.
    Flaharty KK; Caro J; Erslev A; Whalen JJ; Morris EM; Bjornsson TD; Vlasses PH
    Clin Pharmacol Ther; 1990 May; 47(5):557-64. PubMed ID: 2188770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration.
    Sörgel F; Thyroff-Friesinger U; Vetter A; Vens-Cappell B; Kinzig M
    Int J Clin Pharmacol Ther; 2009 Jun; 47(6):391-401. PubMed ID: 19473601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.
    Gladziwa U; Klotz U; Bäumer K; Zollinger R; Mann H; Sieberth HG
    Clin Pharmacokinet; 1993 Aug; 25(2):145-53. PubMed ID: 8403738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
    Markham A; Bryson HM
    Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations.
    Sörgel F; Thyroff-Friesinger U; Vetter A; Vens-Cappell B; Kinzig M
    Pharmacology; 2009; 83(2):122-30. PubMed ID: 19122476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
    Macdougall IC; Gray SJ; Elston O; Breen C; Jenkins B; Browne J; Egrie J
    J Am Soc Nephrol; 1999 Nov; 10(11):2392-5. PubMed ID: 10541299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon
    Yoon S; Rhee SJ; Heo SJ; Oh TY; Yoon SH; Cho JY; Lee S; Yu KS
    Drug Des Devel Ther; 2017; 11():3127-3135. PubMed ID: 29138535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.
    Stalker D; Reid S; Ramaiya A; Wisemandle WA; Martin NE
    Clin Ther; 2016 Aug; 38(8):1778-88. PubMed ID: 27473384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers.
    Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
    Arzneimittelforschung; 2008; 58(5):215-9. PubMed ID: 18589555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.
    Schouten JP; Voorhorst G; Helbing AR; Janssen JW; Diderich PP; Op de Hoek CT
    Pharm World Sci; 1993 Dec; 15(6):252-6. PubMed ID: 8298584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers.
    Cheung WK; Natarajan J; Sanders M; Vercammen E
    Biopharm Drug Dispos; 2000 Sep; 21(6):211-9. PubMed ID: 11304719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
    Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
    Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.